Cargando…
Ibrutinib-induced cardiomyopathy
The use of ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and other hematologic malignancies is blooming. Atrial fibrillation is a known side effect of ibrutinib but cardiomyopathy was not reported previously. We present an 88-year-old man with CLL who was admitted to the hospital...
Autores principales: | Kyi, Htay Htay, Zayed, Yazan, Al Hadidi, Samer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374917/ https://www.ncbi.nlm.nih.gov/pubmed/30788077 http://dx.doi.org/10.1080/20009666.2018.1555432 |
Ejemplares similares
-
Pancreatic Adenocarcinoma Masquerading as Idiopathic Chronic Pancreatitis with Delayed Diagnosis
por: Badami, Sunil, et al.
Publicado: (2017) -
Seizure Associated Takotsubo Syndrome: A Rare Combination
por: Kyi, Htay Htay, et al.
Publicado: (2017) -
A Case of Relapsing Peritoneal Dialysis-Associated Peritonitis by Dokdonella koreensis
por: Tan, Jamie Bee Xian, et al.
Publicado: (2018) -
Association between ibrutinib and mid-cavitary Takotsubo cardiomyopathy: a case report and a review of chemotherapy-induced Takostubo’s cardiomyopathy
por: Giza, Dana Elena, et al.
Publicado: (2017) -
Directed intervention to improve the rate of admission medication reconciliation in an acute care hospital
por: Kyi, Htay Htay, et al.
Publicado: (2019)